(PharmaNewsWire.Com, January 06, 2018 ) North America Autoimmune Monoclonal Antibodies market is expected to reach USD 11,709.7 million by 2021 from USD 7,798.3 million in 2016, growing at a CAGR of 8.47% during forecast period 2016-2021. Irregular functioning of humans’ immune system results in autoimmune disorders. Overproduction of self-reactive immune cells (such as antibodies & T-cells) damage regular functions of /cells/tissues/organs. This lead to different autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and others diseases. Typically, drugs are used as a treatment to cure autoimmune disorders. The adverse effects associated with drugs has made switched to concentrate on monoclonal antibodies.
Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat wide array of diseases that are related to immune response. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells not impacting the normal ones.
Growing number of patients with autoimmune diseases, increasing research and development to promote the development of monoclonal antibodies, presence of large number of biotechnology companies, and rising demand for effective therapeutics are driving the growth of autoimmune monoclonal antibodies market in North America. In addition, increasing innovations in monoclonal antibodies research, rising number of product launches, and growing number of collaborations & agreements to promote autoimmune therapies using monoclonal antibodies are further supporting the growth of autoimmune monoclonal antibodies market in North America. However, stringent regulatory pathways and lack of proper reimbursement policies are expected to limit the growth of autoimmune monoclonal antibodies market in North America.
The key players in Autoimmune Monoclonal Antibodies market include, GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: